SPDEF通过改变β-catenin的转录靶点诱导结直肠癌细胞静息
该研究在结直肠癌小鼠模型、细胞系及人和小鼠正常与肿瘤类器官中探究SPDEF抑制肿瘤的机制。SPDEF表达足以抑制β-catenin激活的肠道肿瘤发生、阻断肿瘤细胞增殖并限制已形成肿瘤的生长,使肿瘤细胞进入静息状态。SPDEF通过蛋白-蛋白相互作用破坏β-catenin与TCF1和TCF3的结合,将其从细胞周期基因增强子区置换,而不影响干细胞活性基因。
要点
- SPDEF表达足以抑制β-catenin激活的肠道肿瘤发生并限制已形成肿瘤生长。
- SPDEF通过蛋白-蛋白相互作用破坏β-catenin与TCF1和TCF3结合。
- SPDEF将β-catenin从细胞周期基因增强子区置换,不影响干细胞活性基因。
核心结论
- 在 mice 和人结直肠癌研究中,SPDEF通过破坏β-catenin与TCF1和TCF3的结合并调控细胞周期基因,诱导结直肠癌细胞静息。
研究设计与样本
- 研究使用了Lgr5CreERT2; β-cateninexon3; Rosa26LSL-rtta-ires-EGFP; TRE-Spdef小鼠模型、HCT116和SW480结直肠癌细胞系(可诱导表达带标签的SPDEF或载体对照,皮下注射入免疫缺陷NSG小鼠),以及可诱导SPDEF的人结肠类器官(包括正常直肠黏膜来源的对照系和携带胚系MUTYH突变的腺癌患者来源系)。
主要发现
- SPDEF表达足以抑制β-catenin激活的肠道肿瘤发生、阻断肿瘤细胞增殖并限制已形成肿瘤的生长。
- 在β-catenin激活的肿瘤细胞中,SPDEF表达诱导静息状态,停止SPDEF表达后该状态可逆转。
- 在小鼠和人正常及肿瘤来源的肠类器官/结肠类器官中,表达SPDEF 3天的类器官显著更小。
- SPDEF通过蛋白-蛋白相互作用抑制β-catenin的转录活性,不依赖SPDEF的DNA结合能力。
- SPDEF破坏β-catenin与TCF1和TCF3的结合,将β-catenin从调控细胞周期的基因增强子区置换,但不影响调控干细胞活性的基因。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The canonical Wnt signaling pathway activates the transcriptional activity of β-catenin. This pathway is often activated in colorectal cancer cells, but strategies to block it in tumors have not been effective. The SAM pointed domain containing ETS transcription factor (SPDEF) suppresses formation of colon tumors by unclear mechanisms. We investigated these mechanisms and the effects of SPDEF on β-catenin activity in mouse models of colorectal cancer (CRC), CRC cell lines, and mouse and human normal and cancer colonoids. METHODS: We performed studies of Lgr5CreERT2; β-cateninexon3; Rosa26LSL-rtta-ires-EGFP; TRE-Spdef mice, which express an oncogenic form of β-catenin in Lgr5-positive ISCs upon administration of tamoxifen and SPDEF upon administration of tetracycline. CRC lines (HCT116 and SW480) were engineered to express inducible tagged SPDEF or vector (control) and subcutaneously injected into immunodeficient NSG mice. We generated SPDEF-inducible human colonoids, including a line derived from normal rectal mucosa (control) and an adenocarcinoma line derived from a patient with germline MUTYH mutation. Full-length and truncated forms of SPDEF were expressed in CRC cells; cells were assayed for β-catenin activity and studied in immunoprecipitation and chromatin immunoprecipitation assays. RESULTS: Expression of SPDEF was sufficient to inhibit intestinal tumorigenesis by activated β-catenin, block tumor cell proliferation, and restrict growth of established tumors. In tumor cells with activated β -catenin, expression of SPDEF induced a quiescent state, which was reversed when SPDEF expression was stopped. In mouse and human normal and tumor-derived enteroids/colonoids, those that expressed SPDEF for 3 days were significantly smaller. SPDEF inhibited the transcriptional activity of β-catenin via a protein-protein interaction, independent of SPDEF DNA binding capacity. SPDEF disrupted β-catenin binding to TCF1 and TCF3, displacing β-catenin from enhancer regions of genes that regulate the cell cycle but not genes that regulate stem cell activities. CONCLUSIONS: In studies of mice and human CRC, we found that SPDEF induces a quiescent state in CRC cells by disrupting binding of β-catenin to TCF1 and TCF3 and regulation of genes that control the cell cycle. In this model, β-catenin activity determines the proliferation or quiescence of CRC cells based on the absence or presence of SPDEF.
引用
- Lo YH, Noah TK, Chen MS, et al. SPDEF Induces Quiescence of Colorectal Cancer Cells by Changing the Transcriptional Targets of β-catenin. Gastroenterology. 2017. PMID: 28390865. doi:10.1053/j.gastro.2017.03.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。